Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
Rosellini P, Amintas S, Caumont C, Veillon R, Galland-Girodet S, Cuguillière A, Nguyen L, Domblides C, Gouverneur A, Merlio JP, Bezin J, Girodet PO. Rosellini P, et al. Eur J Cancer. 2022 Sep;172:85-95. doi: 10.1016/j.ejca.2022.05.026. Epub 2022 Jun 24. Eur J Cancer. 2022. PMID: 35759814
Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data.
Spini A, Hyeraci G, Bartolini C, Donnini S, Rosellini P, Gini R, Ziche M, Salvo F, Roberto G. Spini A, et al. Among authors: rosellini p. Int J Environ Res Public Health. 2021 Jul 19;18(14):7679. doi: 10.3390/ijerph18147679. Int J Environ Res Public Health. 2021. PMID: 34300130 Free PMC article. Review.
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.
Roviello G, Andre F, Venturini S, Pistilli B, Curigliano G, Cristofanilli M, Rosellini P, Generali D. Roviello G, et al. Among authors: rosellini p. Eur J Cancer. 2017 Nov;86:257-265. doi: 10.1016/j.ejca.2017.09.018. Epub 2017 Oct 19. Eur J Cancer. 2017. PMID: 29055841 Free article. Review.
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guiñazú J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Hardt K, et al. Lancet Infect Dis. 2022 Dec;22(12):1703-1715. doi: 10.1016/S1473-3099(22)00506-0. Epub 2022 Sep 13. Lancet Infect Dis. 2022. PMID: 36113538 Free PMC article. Clinical Trial.
First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective.
Spini A, Gini R, Rosellini P, Singier A, Bellan C, Pascucci A, Leoncini L, Mathieu C, Martellucci I, Furiesi F, Giorgi S, Donnini S, Roberto G, Ziche M, Salvo F. Spini A, et al. Among authors: rosellini p. Cancers (Basel). 2021 Dec 5;13(23):6129. doi: 10.3390/cancers13236129. Cancers (Basel). 2021. PMID: 34885238 Free PMC article.
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
Corona SP, Roviello G, Strina C, Milani M, Madaro S, Zanoni D, Allevi G, Aguggini S, Cappelletti MR, Francaviglia M, Azzini C, Cocconi A, Sirico M, Bortul M, Zanconati F, Giudici F, Rosellini P, Meani F, Pagani O, Generali D. Corona SP, et al. Among authors: rosellini p. Breast. 2019 Aug;46:19-24. doi: 10.1016/j.breast.2019.04.004. Epub 2019 Apr 25. Breast. 2019. PMID: 31051411
20 results